Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What HappenedDefense World · Oct 11, 2026
Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?Defense World · Oct 5, 2026
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual MeetingGlobeNewsWire · Oct 1, 2026
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to BuyFool - Investing News · Sep 30, 2026
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide InjectionGlobeNewsWire · Sep 30, 2026
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug ApprovalSeeking Alpha · Sep 17, 2026Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.